Tyrnovo Ltd.
🇮🇱Israel
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
Phase 1
Active, not recruiting
- Conditions
- Squamous Cell Carcinoma of Head and NeckColorectal AdenocarcinomaHead and Neck CancerSolid Tumor, AdultMetastatic Solid TumorRecurrent Solid Tumor
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- TyrNovo Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT04474470
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸UCSD Moores Cancer Center, San Diego, California, United States
© Copyright 2025. All Rights Reserved by MedPath